Clinic Roundup

• Cytokinetics Inc., of South San Francisco, reported results from two Phase II studies of CK-2017357 in amyotrophic lateral sclerosis (ALS), showing that the drug was safe and well tolerated when dosed with Rilutek (riluzole, Sanofi SA), the only approved treatment for ALS. Data were presented at the Academy of Neurology meeting in New Orleans.